# Mark Egly Foundation - Theory of Change Framework

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Strategy Team
**Purpose**: Map how the foundation's activities lead to measurable impact and ultimate goals

---

## ðŸ“‹ Table of Contents

1. [Theory of Change Overview](#theory-of-change-overview)
2. [The Problem Analysis](#the-problem-analysis)
3. [Our Solution Framework](#our-solution-framework)
4. [Logic Model](#logic-model)
5. [Causal Pathways](#causal-pathways)
6. [Assumptions & Risks](#assumptions--risks)
7. [Impact Measurement](#impact-measurement)

---

## Theory of Change Overview

### What is a Theory of Change?

A Theory of Change is a roadmap that explains:

- **WHY** change is needed (the problem)
- **WHAT** we'll do about it (our activities)
- **HOW** change happens (causal pathways)
- **EVIDENCE** that it's working (measurement)

It connects our daily work to our ultimate vision: **A world where no one suffers from undiagnosed AATD.**

### Our Theory of Change in One Sentence

> If we educate physicians, support patients, advance research, and advocate for policy change, then diagnostic delays will decrease, outcomes will improve, and AATD will transform from an overlooked orphan disease into a well-managed condition with early detection and comprehensive support.

---

## The Problem Analysis

### Core Problem Statement

**Alpha-1 Antitrypsin Deficiency (AATD) patients suffer from preventable harm due to delayed diagnosis.**

### Problem Breakdown

**The Diagnostic Delay Crisis**:

```
Current Reality:
â”œâ”€ Average time to diagnosis: 7-8 YEARS
â”œâ”€ Average physicians consulted: 4+
â”œâ”€ Common misdiagnoses: Asthma, COPD, "unknown"
â””â”€ Outcome: Preventable lung damage, delayed treatment, reduced quality of life

Root Causes:
â”œâ”€ Physician Knowledge Gap
â”‚   â”œâ”€ AATD not taught comprehensively in medical school
â”‚   â”œâ”€ Rare disease = low awareness
â”‚   â””â”€ No standard screening protocols
â”œâ”€ Testing Barriers
â”‚   â”œâ”€ Genetic testing not routine
â”‚   â”œâ”€ Cost concerns (insurance coverage)
â”‚   â””â”€ Lack of accessible testing options
â”œâ”€ Patient Awareness Gap
â”‚   â”œâ”€ Most patients never heard of AATD
â”‚   â”œâ”€ Don't know testing is available
â”‚   â””â”€ Symptoms dismissed as "just asthma"
â”œâ”€ Policy Gaps
â”‚   â”œâ”€ No newborn screening mandate
â”‚   â”œâ”€ No protected status
â”‚   â””â”€ Inconsistent insurance coverage
â””â”€ System Failures
    â”œâ”€ No cascade testing protocols
    â”œâ”€ Fragmented care coordination
    â””â”€ Limited research funding (orphan disease)
```

### Who Is Affected?

**Direct Impact**:

- **~100,000 Americans** with diagnosed AATD (estimated)
- **~300,000+ undiagnosed** (conservative estimate)
- **Millions of carriers** (MZ genotype) with emerging evidence of health risks

**Ripple Effects**:

- **Families**: Inherited condition affects multiple generations
- **Healthcare system**: Increased costs from late diagnosis
- **Employers**: Lost productivity from untreated illness
- **Society**: Preventable disability and early mortality

### Consequences of Inaction

**For Individuals**:

- Progressive lung damage during diagnostic delay
- Reduced quality of life
- Premature disability or death
- Emotional toll of undiagnosed suffering
- Financial burden of ineffective treatments

**For Healthcare System**:

- Higher costs (late-stage treatment is expensive)
- Physician malpractice risk
- Inefficient use of resources (treating wrong diagnosis)

**For Society**:

- Lost human potential
- Preventable disability claims
- Missed research opportunities
- Orphan disease remains neglected

---

## Our Solution Framework

### Vision: The World We Want to Create

**By 2035**:

- **Universal newborn screening** for AATD
- **<1 year diagnostic time** (from 7-8 years)
- **Every physician trained** to recognize AATD
- **Comprehensive patient support** for all
- **Breakthrough treatments** available
- **Protected status** and full insurance coverage

### Mission: How We Get There

**Education + Research + Advocacy + Support = Systemic Change**

We attack the problem from four angles simultaneously:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  1. EDUCATE                                      â”‚
â”‚  Physicians, Patients, Public                    â”‚
â”‚  â†’ Increases awareness & early recognition       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  2. SUPPORT                                      â”‚
â”‚  Financial Aid, Navigation, Community            â”‚
â”‚  â†’ Removes barriers to testing & treatment       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  3. RESEARCH                                     â”‚
â”‚  Innovation, Data, Better Tools                  â”‚
â”‚  â†’ Accelerates breakthroughs in detection        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  4. ADVOCATE                                     â”‚
â”‚  Policy Change, Systems Reform                   â”‚
â”‚  â†’ Creates lasting institutional change          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
              â”‚   IMPACT    â”‚
              â”‚ Diagnostic  â”‚
              â”‚   Delays    â”‚
              â”‚  Eliminated â”‚
              â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Logic Model

### Inputs â†’ Activities â†’ Outputs â†’ Outcomes â†’ Impact

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ INPUTS (What we invest)                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ Funding: Grants, donations, licensing revenue                     â”‚
â”‚ â€¢ Expertise: Medical advisors, researchers, patient advocates       â”‚
â”‚ â€¢ Partners: Academic institutions, pharma, patient orgs             â”‚
â”‚ â€¢ Technology: Website, database, testing innovations                â”‚
â”‚ â€¢ Mark's Patent: Repurposing AAT protein applications               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ACTIVITIES (What we do)                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ EDUCATION                                                           â”‚
â”‚ â€¢ Develop CME courses for physicians                                â”‚
â”‚ â€¢ Create patient education materials                                â”‚
â”‚ â€¢ Launch public awareness campaigns                                 â”‚
â”‚ â€¢ Build AATD Certification Seal Program                             â”‚
â”‚                                                                     â”‚
â”‚ SUPPORT                                                             â”‚
â”‚ â€¢ Provide financial assistance (testing, treatment)                 â”‚
â”‚ â€¢ Offer patient navigation services                                 â”‚
â”‚ â€¢ Build Alpha1Life.com community platform                           â”‚
â”‚ â€¢ Facilitate support groups                                         â”‚
â”‚                                                                     â”‚
â”‚ RESEARCH                                                            â”‚
â”‚ â€¢ Fund AAT glucometer device development                            â”‚
â”‚ â€¢ Support rapid testing innovations                                 â”‚
â”‚ â€¢ Build anonymous data donation program                             â”‚
â”‚ â€¢ Partner on gene therapy research                                  â”‚
â”‚                                                                     â”‚
â”‚ ADVOCACY                                                            â”‚
â”‚ â€¢ Draft model newborn screening legislation                         â”‚
â”‚ â€¢ Advocate for insurance coverage mandates                          â”‚
â”‚ â€¢ Push for occupational health policies                             â”‚
â”‚ â€¢ Build coalitions with rare disease groups                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ OUTPUTS (What we produce)                                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ EDUCATION                                                           â”‚
â”‚ â€¢ X physicians trained via CME courses                              â”‚
â”‚ â€¢ Y medical institutions certified "AATD Aware"                     â”‚
â”‚ â€¢ Z patient education materials distributed                         â”‚
â”‚ â€¢ Public awareness campaign reaching M people                       â”‚
â”‚                                                                     â”‚
â”‚ SUPPORT                                                             â”‚
â”‚ â€¢ $X in patient assistance distributed                              â”‚
â”‚ â€¢ Y patients served by navigation program                           â”‚
â”‚ â€¢ Z active community members on Alpha1Life                          â”‚
â”‚ â€¢ M support group meetings held                                     â”‚
â”‚                                                                     â”‚
â”‚ RESEARCH                                                            â”‚
â”‚ â€¢ $X in research grants awarded                                     â”‚
â”‚ â€¢ Y research partnerships established                               â”‚
â”‚ â€¢ Z patients contributed data                                       â”‚
â”‚ â€¢ AAT glucometer prototype developed                                â”‚
â”‚                                                                     â”‚
â”‚ ADVOCACY                                                            â”‚
â”‚ â€¢ X states introduced newborn screening bills                       â”‚
â”‚ â€¢ Y meetings with policymakers                                      â”‚
â”‚ â€¢ Z coalition partners engaged                                      â”‚
â”‚ â€¢ Model legislation drafted and published                           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ SHORT-TERM OUTCOMES (1-2 years)                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ AWARENESS                                                           â”‚
â”‚ â€¢ Physicians more likely to test for AATD                           â”‚
â”‚ â€¢ Patients aware AATD exists and testing available                  â”‚
â”‚ â€¢ Public recognizes AATD as serious condition                       â”‚
â”‚                                                                     â”‚
â”‚ ACCESS                                                              â”‚
â”‚ â€¢ Testing more affordable and accessible                            â”‚
â”‚ â€¢ Treatment financially viable for more patients                    â”‚
â”‚ â€¢ Support resources available to newly diagnosed                    â”‚
â”‚                                                                     â”‚
â”‚ INNOVATION                                                          â”‚
â”‚ â€¢ New testing technologies in development                           â”‚
â”‚ â€¢ Research pipeline advancing                                       â”‚
â”‚ â€¢ Data infrastructure established                                   â”‚
â”‚                                                                     â”‚
â”‚ POLICY MOMENTUM                                                     â”‚
â”‚ â€¢ Legislative champions identified                                  â”‚
â”‚ â€¢ Coalitions formed                                                 â”‚
â”‚ â€¢ Model policies drafted                                            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ MEDIUM-TERM OUTCOMES (3-5 years)                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ DIAGNOSTIC IMPROVEMENT                                              â”‚
â”‚ â€¢ Average diagnostic time reduced to 3-4 years                      â”‚
â”‚ â€¢ More patients diagnosed before significant damage                 â”‚
â”‚ â€¢ Cascade testing becoming standard practice                        â”‚
â”‚                                                                     â”‚
â”‚ SYSTEM CHANGE                                                       â”‚
â”‚ â€¢ 5-10 states adopt newborn screening                               â”‚
â”‚ â€¢ Major insurance companies cover AATD testing                      â”‚
â”‚ â€¢ Medical schools integrate AATD into curriculum                    â”‚
â”‚ â€¢ AATD certification seal recognized nationally                     â”‚
â”‚                                                                     â”‚
â”‚ RESEARCH BREAKTHROUGHS                                              â”‚
â”‚ â€¢ AAT glucometer commercially available                             â”‚
â”‚ â€¢ Rapid DNA testing simplified                                      â”‚
â”‚ â€¢ Gene therapy trials showing promise                               â”‚
â”‚ â€¢ MZ carrier risks better understood                                â”‚
â”‚                                                                     â”‚
â”‚ COMMUNITY STRENGTH                                                  â”‚
â”‚ â€¢ Thriving patient community (Alpha1Life)                           â”‚
â”‚ â€¢ Patient navigation program at scale                               â”‚
â”‚ â€¢ National recognition of foundation                                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ LONG-TERM OUTCOMES (5-10 years)                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ SYSTEMIC TRANSFORMATION                                             â”‚
â”‚ â€¢ Diagnostic delay reduced to <1 year                               â”‚
â”‚ â€¢ Universal newborn screening (all 50 states)                       â”‚
â”‚ â€¢ AATD recognized as protected condition                            â”‚
â”‚ â€¢ Standard cascade testing protocols                                â”‚
â”‚ â€¢ Occupational screening for high-risk jobs                         â”‚
â”‚                                                                     â”‚
â”‚ IMPROVED OUTCOMES                                                   â”‚
â”‚ â€¢ Preserved lung function in diagnosed patients                     â”‚
â”‚ â€¢ Reduced early mortality                                           â”‚
â”‚ â€¢ Improved quality of life                                          â”‚
â”‚ â€¢ Reduced healthcare costs (early intervention)                     â”‚
â”‚                                                                     â”‚
â”‚ INNOVATION ECOSYSTEM                                                â”‚
â”‚ â€¢ Multiple testing/treatment innovations available                  â”‚
â”‚ â€¢ Robust research infrastructure                                    â”‚
â”‚ â€¢ Gene therapy options available                                    â”‚
â”‚ â€¢ Mark's patent applications improving lives                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ULTIMATE IMPACT (10+ years)                                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… No one suffers from undiagnosed AATD                             â”‚
â”‚ âœ… AATD transformed from overlooked to well-managed                 â”‚
â”‚ âœ… Early detection is universal                                     â”‚
â”‚ âœ… Comprehensive support for every patient                          â”‚
â”‚ âœ… Continuous innovation in treatment                               â”‚
â”‚ âœ… Model for other orphan disease advocacy                          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Causal Pathways

### Pathway 1: Education â†’ Early Diagnosis

**If-Then Logic**:

```
IF we educate physicians about AATD symptoms and risk factors
  THEN they will test for AATD more frequently

IF physicians test more frequently
  THEN more patients will be diagnosed earlier

IF patients are diagnosed earlier
  THEN they can start treatment before significant damage

IF treatment starts earlier
  THEN lung function is preserved and outcomes improve
```

**Evidence Supporting This Pathway**:

- âœ… Physician knowledge is #1 barrier to diagnosis (literature)
- âœ… CME courses shown to change clinical practice
- âœ… Early AAT augmentation therapy slows progression
- âœ… Diagnostic delay correlates with worse outcomes

**Key Intervention**:

- **CME Courses**: "Recognizing AATD in Primary Care"
- **Certification Program**: "AATD Aware" seal for institutions
- **Diagnostic Protocols**: Decision trees for when to test

**Measurement**:

- % of physicians who complete training
- % of physicians who report testing more
- Reduction in average diagnostic time
- Number of new diagnoses annually

---

### Pathway 2: Support â†’ Reduced Barriers

**If-Then Logic**:

```
IF we provide financial assistance for testing
  THEN more at-risk patients will get tested

IF more patients get tested
  THEN more AATD cases are identified

IF we provide patient navigation
  THEN patients access appropriate care faster

IF patients access care faster
  THEN treatment starts sooner and outcomes improve
```

**Evidence Supporting This Pathway**:

- âœ… Cost is a barrier to genetic testing (research)
- âœ… Patient navigation improves health outcomes (evidence-based)
- âœ… AATD patients report feeling "lost" in healthcare system
- âœ… Peer support improves mental health and adherence

**Key Interventions**:

- **Testing Grants**: Cover cost of genetic testing
- **Treatment Assistance**: Help pay for AAT augmentation
- **Patient Navigation**: 1-on-1 guidance through system
- **Alpha1Life Community**: Peer support and resources

**Measurement**:

- Number of tests funded â†’ diagnoses made
- Patient satisfaction with navigation (NPS)
- Time from diagnosis to first treatment
- Community engagement metrics

---

### Pathway 3: Research â†’ Better Tools

**If-Then Logic**:

```
IF we fund development of AAT glucometer device
  THEN patients can monitor their AAT levels easily

IF patients monitor AAT levels
  THEN declining levels are caught early

IF declining levels are caught early
  THEN interventions can prevent exacerbations

IF exacerbations are prevented
  THEN long-term outcomes improve

---

IF we develop rapid DNA testing
  THEN testing becomes faster and more accessible

IF testing is more accessible
  THEN more people get tested

IF more people get tested
  THEN diagnostic delays decrease
```

**Evidence Supporting This Pathway**:

- âœ… Real-time monitoring improves chronic disease management (diabetes model)
- âœ… Simplified testing increases uptake (HIV testing example)
- âœ… Innovation accelerates with targeted funding
- âœ… Patient-generated data valuable for research

**Key Interventions**:

- **AAT Glucometer**: Portable monitoring device
- **Rapid DNA Testing**: Simplified genetic testing
- **Data Donation Program**: Build research database
- **Mark's Patent**: Repurposing AAT protein applications

**Measurement**:

- Device development milestones
- Research grants awarded â†’ publications produced
- Patients enrolled in data donation program
- Patent licensing agreements signed

---

### Pathway 4: Advocacy â†’ Systems Change

**If-Then Logic**:

```
IF we advocate for newborn screening legislation
  THEN states will include AATD in screening panels

IF newborns are screened for AATD
  THEN every case is identified at birth

IF cases are identified at birth
  THEN families can make informed decisions

IF families are informed
  THEN carriers avoid risk factors (smoking, exposures)

IF risk factors are avoided
  THEN disease progression is prevented or slowed

---

IF we secure protected status for AATD
  THEN insurance companies cannot discriminate

IF discrimination is prevented
  THEN patients have full access to coverage

IF coverage is accessible
  THEN financial barriers to treatment are removed
```

**Evidence Supporting This Pathway**:

- âœ… Newborn screening works (PKU, cystic fibrosis precedent)
- âœ… Protected status improves access (ADA example)
- âœ… Policy change creates lasting systemic impact
- âœ… Rare disease coalitions successful at advocacy

**Key Interventions**:

- **Model Legislation**: Draft newborn screening bills
- **Coalition Building**: Partner with rare disease orgs
- **Grassroots Advocacy**: Patient stories to legislators
- **Insurance Reform**: Mandate coverage for testing/treatment

**Measurement**:

- Number of states with introduced/passed bills
- Insurance companies covering AATD testing
- Occupational health policies adopted
- Media coverage and public awareness

---

## Assumptions & Risks

### Critical Assumptions

**For Education Pathway to Work**:

1. âœ… Physicians are willing to learn (generally true)
2. âš ï¸ CME courses will change clinical behavior (needs measurement)
3. âœ… AATD testing is available in most areas (mostly true)
4. âš ï¸ Insurance will cover testing (varies by plan)

**For Support Pathway to Work**:

1. âœ… Financial barriers exist (research-backed)
2. âœ… Patients want community and navigation (patient feedback)
3. âš ï¸ We can reach patients who need help (marketing challenge)
4. âœ… Peer support improves outcomes (evidence-based)

**For Research Pathway to Work**:

1. âš ï¸ AAT glucometer is technically feasible (in development)
2. âš ï¸ Patients will use monitoring device (adoption challenge)
3. âœ… Simplified testing will increase uptake (precedent exists)
4. âš ï¸ Mark's patent will generate revenue (market dependent)

**For Advocacy Pathway to Work**:

1. âš ï¸ Legislators will prioritize rare diseases (requires pressure)
2. âš ï¸ Newborn screening expansion politically feasible (state-by-state)
3. âœ… Patient stories influence policy (proven tactic)
4. âš ï¸ Coalitions will form (relationship-building required)

### Risks & Mitigation

**Risk 1: Funding Scarcity**

- **Risk**: Insufficient funding to execute programs at scale
- **Mitigation**: Diversify revenue (grants, donations, patent licensing)
- **Contingency**: Start with high-impact, low-cost initiatives

**Risk 2: Physician Adoption**

- **Risk**: Physicians don't change behavior despite education
- **Mitigation**: Tie to malpractice risk, make testing easy
- **Contingency**: Focus on high-volume institutions first

**Risk 3: Innovation Delays**

- **Risk**: AAT glucometer takes longer/costs more than expected
- **Mitigation**: Partner with established medical device companies
- **Contingency**: Pursue multiple innovation paths simultaneously

**Risk 4: Policy Barriers**

- **Risk**: Newborn screening legislation stalls or fails
- **Mitigation**: Build broad coalitions, use patient advocates
- **Contingency**: Focus on states with rare disease champions

**Risk 5: Patient Reach**

- **Risk**: Can't find undiagnosed patients (they don't know to look)
- **Mitigation**: Public awareness campaigns, physician referrals
- **Contingency**: Partner with asthma/COPD organizations

---

## Impact Measurement

### How We Know We're Succeeding

**Tier 1: Ultimate Impact (Our North Star)**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PRIMARY IMPACT METRIC                           â”‚
â”‚ Diagnostic Delay Time                           â”‚
â”‚                                                 â”‚
â”‚ Baseline: 7-8 years (current)                   â”‚
â”‚ 3-Year Target: 3-4 years                        â”‚
â”‚ 5-Year Target: 1-2 years                        â”‚
â”‚ 10-Year Target: <1 year                         â”‚
â”‚                                                 â”‚
â”‚ How We Measure:                                 â”‚
â”‚ - Survey newly diagnosed patients               â”‚
â”‚ - Track time from symptom onset to diagnosis    â”‚
â”‚ - Compare to historical baseline                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Tier 2: Outcome Metrics (Are we achieving outcomes?)**

**Education Outcomes**:

- % of primary care physicians aware of AATD
- % of physicians who tested for AATD in last year
- # of medical institutions "AATD Aware" certified

**Support Outcomes**:

- # of patients receiving financial assistance
- Patient satisfaction score (NPS)
- Community engagement (monthly active users)

**Research Outcomes**:

- # of research partnerships established
- Innovation milestones achieved (glucometer progress)
- # of patients in data donation program

**Advocacy Outcomes**:

- # of states with newborn screening legislation
- % of insurance companies covering AATD testing
- Media impressions and public awareness

**Tier 3: Output Metrics (Are we doing what we said?)**

**Education Outputs**:

- # of CME courses delivered
- # of physicians trained
- # of patient education materials distributed

**Support Outputs**:

- $ distributed in patient assistance
- # of patient navigation sessions
- # of support group meetings

**Research Outputs**:

- $ in research grants awarded
- # of research publications supported
- AAT glucometer development stage

**Advocacy Outputs**:

- # of legislative meetings
- # of coalition partners
- # of policy briefs published

**Tier 4: Activity Metrics (Are we executing?)**

- Staff time allocation by program area
- Budget spent by program area
- Donor retention rate
- Volunteer hours contributed

### Data Collection Methods

**Baseline Measurement** (Year 0):

- Literature review of current diagnostic delay data
- Survey of AATD patients about their diagnostic journey
- Physician survey on AATD awareness
- Insurance coverage analysis

**Ongoing Tracking**:

- Program participation data (CRM)
- Patient surveys (quarterly)
- Physician surveys (annual)
- Policy tracking database
- Research publication tracking
- Financial reporting (monthly)

**Annual Impact Assessment**:

- Compare metrics to baseline and targets
- Patient outcome surveys
- Stakeholder interviews
- External evaluation (every 3 years)

---

## Theory of Change Validation

### How We'll Know If Our Theory Is Correct

**Short-Term Tests** (1-2 years):

- âœ… Physicians who take our CME course report testing more
- âœ… Patients who receive navigation reach treatment faster
- âœ… Financial assistance removes barriers to testing
- âœ… Public awareness increases after campaigns

**Medium-Term Tests** (3-5 years):

- âœ… Diagnostic time decreases in areas with trained physicians
- âœ… States with advocacy efforts introduce legislation
- âœ… Research innovations move toward commercialization
- âœ… Community members report better outcomes

**Long-Term Tests** (5-10 years):

- âœ… Diagnostic delay significantly reduced (measurable)
- âœ… Policy wins achieved (newborn screening adopted)
- âœ… Innovations available (AAT glucometer on market)
- âœ… AATD nationally recognized condition

### Course Correction

**We will pivot if**:

- Education doesn't change physician behavior â†’ Focus on systems/policy
- Financial assistance isn't the barrier â†’ Focus on awareness/access
- Innovation too slow/expensive â†’ Focus on existing tools
- Policy advocacy not gaining traction â†’ Focus on medical system change

**We will adapt by**:

- Quarterly program reviews
- Annual strategic planning
- Stakeholder feedback loops
- Data-driven decision making
- Willingness to experiment and learn

---

## Summary: Our Theory in Action

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    THE PROBLEM                           â”‚
â”‚                                                          â”‚
â”‚  7-8 year diagnostic delay â†’ preventable harm           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    OUR SOLUTION                          â”‚
â”‚                                                          â”‚
â”‚  Educate + Support + Research + Advocate                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                  CAUSAL PATHWAYS                         â”‚
â”‚                                                          â”‚
â”‚  â€¢ Physician education â†’ earlier testing                 â”‚
â”‚  â€¢ Patient support â†’ reduced barriers                    â”‚
â”‚  â€¢ Research funding â†’ better tools                       â”‚
â”‚  â€¢ Policy advocacy â†’ systemic change                     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                 MEASURABLE OUTCOMES                      â”‚
â”‚                                                          â”‚
â”‚  â€¢ Diagnostic delay decreases                            â”‚
â”‚  â€¢ More patients diagnosed early                         â”‚
â”‚  â€¢ Better health outcomes                                â”‚
â”‚  â€¢ Policy wins achieved                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                   ULTIMATE IMPACT                        â”‚
â”‚                                                          â”‚
â”‚  No one suffers from undiagnosed AATD                    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

**Approved by**: Mark Egly Foundation Board of Directors
**Effective Date**: November 7, 2025
**Version**: 1.0
**Next Review**: November 2026

---

_"Our theory is simple: If we attack the problem from all anglesâ€”education, support, research, advocacyâ€”we will eliminate diagnostic delays and save lives."_

**â€” Mark Egly Foundation Strategy Team**
